Inhibition of colon cancer by Indomethacin and Juglone is a promising approach for the prevention and treatment of colon cancer. The study conducted by A. Seetha highlights the potential of these two compounds in suppressing the development and progression of colon cancer. Colon cancer is a major health problem worldwide, and chemoprevention is a promising approach to reduce the incidence and mortality of this disease. Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), and Juglone, a natural compound found in walnuts and other plants, have been shown to have chemopreventive effects against colon cancer. Both compounds are known to induce apoptosis, cell cycle arrest, and inhibit tumor growth, angiogenesis, and metastasis in colon cancer cells. The mechanisms of action of Indomethacin and Juglone involve the modulation of several signaling pathways involved in cancer development and progression. Indomethacin inhibits the activity of cyclooxygenase-2 (COX-2), an enzyme that plays a critical role in the production of prostaglandin E2 (PGE2), a key mediator of inflammation and tumor growth. Inhibition of COX-2 and PGE2 has been shown to suppress the activity of nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways, which are important for the survival and proliferation of cancer cells. Juglone has been shown to inhibit the Wnt/β-catenin, Notch, and Hedgehog signaling pathways, which are critical for the development and maintenance of colon cancer stem cells. Indomethacin and Juglone also modulate the expression of several key genes and proteins involved in the regulation of apoptosis, cell cycle progression, oxidative stress, and inflammation. Indomethacin induces the expression of caspases and Bax, and inhibits the expression of Bcl-2, leading to the induction of apoptosis in cancer cells. Juglone induces the expression of Nrf2, a transcription factor that regulates the expression of antioxidant and detoxification genes, leading to the reduction of oxidative stress in cancer cells. Preclinical and clinical studies have shown promising results for the use of Indomethacin and Juglone in the prevention and treatment of colon cancer. In preclinical studies, both compounds have been shown to inhibit the growth of colon cancer cells in vitro and in vivo, and to suppress the development of colon tumors in animal models. Clinical trials have also shown promising results for the use of Indomethacin and Juglone in the prevention and treatment of colon cancer, with minimal side effects. In conclusion, the study conducted by A. Seetha highlights the potential of Indomethacin and Juglone as chemopreventive agents for colon cancer. The mechanisms of action of these compounds involve the modulation of several signaling pathways involved in cancer development and progression, as well as the regulation of key genes and proteins involved in apoptosis, cell cycle progression, oxidative stress, and inflammation. Further studies are needed to fully understand the potential of these compounds and to develop effective strategies for their use in the prevention and treatment of colon cancer.
外文書商品之書封，為出版社提供之樣本。實際出貨商品，以出版社所提供之現有版本為主。部份書籍，因出版社供應狀況特殊，匯率將依實際狀況做調整。
無庫存之商品，在您完成訂單程序之後，將以空運的方式為你下單調貨。為了縮短等待的時間，建議您將外文書與其他商品分開下單，以獲得最快的取貨速度，平均調貨時間為1~2個月。
為了保護您的權益，「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。
若要辦理退貨，請在商品鑑賞期內寄回，且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。
